Indivior Welcomes Vanessa Procter as New Executive VP of Corporate Affairs

Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs

Indivior PLC has recently announced the appointment of Vanessa Procter to the position of Executive Vice President of Corporate Affairs, effective from July 7, 2025. With a distinguished career in the biopharmaceutical sector, Procter brings a wealth of experience to her new role. At Indivior, she will be overseeing various crucial aspects of corporate and public affairs, including Corporate Communications, Government Affairs, Policy, and Advocacy.

Joe Ciaffoni, the CEO of Indivior, expressed his enthusiasm regarding Procter's appointment, highlighting her exceptional ability to unify teams around shared objectives and implement effective strategies aimed at improving patient access within complex regulatory frameworks. He stated, “We look forward to her expertise and invaluable contributions as we pursue our mission to transform the lives of people living with opioid use disorder.”

In her own words, Procter echoed her excitement, stating, “I am honored to join Indivior at this transformative time for the Company. Public policy and community engagement are critical to address this significant public health challenge; providing the framework, funding, and systems necessary to ensure treatment in the right place and at the right time.” She emphasizes the importance of collaboration with the company’s stakeholders and the communities they serve in addressing the opioid crisis.

Vanessa Procter has dedicated the last 25 years of her career to the biopharmaceutical field, holding key positions in corporate and government affairs at various organizations. Her most recent role was as Senior Vice President of Corporate Affairs at Sage Therapeutics, where she successfully spearheaded the launch of ZURZUVAE™, a groundbreaking treatment for postpartum depression. In that capacity, she supervised multiple departments including corporate communications, investor relations, government affairs, and patient advocacy.

Before her tenure at Sage Therapeutics, Procter was the Head of U.S. Government Affairs and Public Policy at Alexion Pharmaceuticals, where she played a pivotal role in expanding patient access to both existing and innovative therapies. Her experience also includes a position as Director of Federal Government Affairs at MedImmune, along with serving as a health policy adviser in the U.S. House of Representatives.

Procter’s educational background includes a Bachelor of Arts degree in History from Gettysburg College.

Founded in Richmond, Virginia, Indivior is a global pharmaceutical company focused on creating innovative therapies for the treatment of opioid use disorder (OUD). The company aims to transform OUD from a global health crisis into a chronic disease that is recognized and treated effectively. With a diverse portfolio of OUD medications and a robust pipeline of prospective new therapies, Indivior is dedicated to making evidence-based treatment accessible for patients worldwide. The company's commitment is evident in its employee base of over 1,000 people and the availability of its products in more than 30 countries. For more information about Indivior’s mission and initiatives, visit Indivior's official website. Connect with them on LinkedIn as well for more updates on their progress and projects.